Digital Biomarkers in ALS
Time & Location
About the Event
We are excited to host EverythingALS Community Event: Use of Digital Biomarkers in ALS.
We invite you to join us and other people with ALS and families to engage in a positive setting of collaboration and community.
The meeting will be on Wednesday, May 5th 2021 at 4:00 pm PT
-5:00pm Mountain Time
-6:00pm Central Time
-7:00pm Eastern Time
The meeting will be approximately 45-60mins long followed by an open forum.
Once you RSVP the Zoom details with password will be sent via email. Watch out for the email. If you have any questions please email us at email@example.com.
Our speaker Dr. James Berry, Director of MGH Neurological Clinical Reserach Institute and Chief of the Division of ALS and Motor Neuron Diseases.
Dr. Berry provides care for people with amyotrophic lateral sclerosis (ALS). He is the Winthrop Family Scholar in ALS Sciences, the Director of the Massachusetts General Hospital (MGH) multidisciplinary ALS clinic and Chief of the Division of ALS and Motor Neuron Diseases. He has worked to better serve people with ALS by building the tools and team required to extend the reach of the MGH clinic team beyond the walls of the physical clinic. The ALS House Call program and video televisit program are examples of exciting initiatives at the MGH ALS clinic.
Dr. Berry works as an ALS researcher, designing, overseeing, and carrying out trials at MGH and centers across the country. His work is focused on the identification of markers of ALS in blood and spinal fluid, with an emphasis on markers of abnormal inflammation. He collaborates broadly with researchers around the globe on these biomarker efforts. He is also actively working to develop mobile health and digital phenotyping methods to better understand ALS and hasten the development of new therapies, while reducing the burden of trial participation for people with ALS.
Dr. Berry is also the Director of the MGH Neurological Clinical Research Institute (NCRI) and Director of the Mass General Brigham Neurodegenerative Clinical Research Fellowship. He is a member of the Massachusetts ALS Registry team and CDC/ATSDR National ALS Registry and Biorepository Expert Panels. In addition, he is on the Executive Committee of the NEALS Consortium, a national organization for ALS clinical researchers, where he also leads the NEALS Biorepository and Technology in ALS subcommittee.
We look forward to seeing you at the event!